Gamma Medica and Alpha Imaging said today they inked a distribution agreement, with Alpha Imaging picking up Gamma’s LumaGem molecular breast imaging device for distribution in the Midwest and Mid-Atlantic regions.
The LumaGem molecular breast imaging device is designed to improve the detection of early cancers in individuals with dense breast tissue and complex mammograms, according to the companies.
“Alpha Imaging’s product reach in Women’s Healthcare is further enhanced with Molecular Breast Imaging. We look forward to the partnership as we continue to provide best-in-class products and services to our customers while expanding and growing our business,” Alpha Imaging CEO Michael Perrico said in a press release.
Recent studies of MBI used on individuals with dense breast tissue report a 4 times higher rate of invasive breast cancer detection as a secondary screening protocol and 50% reduced rate of biopsies, the companies said.
“Alpha Imaging has generated trusted partnerships with their customers, helping to strengthen their already great position within their women’s healthcare market. We are excited to partner and provide the world’s leading MBI solution with Alpha Imaging’s extensive customer relationships expanding to over 1,100 healthcare facilities throughout the Midwest and Mid-Atlantic,” Gamma Medico CEO Philip Croxford said in prepared remarks.